Lamotrigine Bioequivalence

PHASE4CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Epilepsy
Interventions
DRUG

Brand lamotrigine

Brand lamotrigine tablet 100mg tablets (1-3 either once or twice a day) for two weeks

DRUG

Generic lamotrigine

Generic lamotrigine tablet 100mg tablets (1-3 either once or twice a day) for two weeks

Trial Locations (1)

21201

University of Maryland, Baltimore

All Listed Sponsors
collaborator

Food and Drug Administration (FDA)

FED

lead

University of Maryland, Baltimore

OTHER

NCT01995825 - Lamotrigine Bioequivalence | Biotech Hunter | Biotech Hunter